Lincoln Pharma
Ticker > Company >

Lincoln Pharma share price

Lincoln Pharmaceuticals Ltd.

NSE: LINCOLN BSE: 531633 SECTOR: Pharmaceuticals & Drugs  78k   329   48

558.65
0 0
BSE: 23 May 04:01 PM

Price Summary

Today's High

₹ 560

Today's Low

₹ 539.55

52 Week High

₹ 975

52 Week Low

₹ 498

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 1118.96 Cr.

Enterprise Value

₹ 1106.64 Cr.

No. of Shares

2 Cr.

P/E

13.59

P/B

1.67

Face Value

₹ 10

Div. Yield

0.32 %

Book Value (TTM)

₹  335.34

CASH

₹ 13.39 Cr.

DEBT

₹ 1.07 Cr.

Promoter Holding

49.78 %

EPS (TTM)

₹  41.11

Sales Growth

13.76%

ROE

17.04 %

ROCE

22.53%

Profit Growth

27.99 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year13.76%
3 Year11.14%
5 Year10.46%

Profit Growth

1 Year27.99%
3 Year14.44%
5 Year14.88%

ROE%

1 Year17.04%
3 Year16.66%
5 Year17.2%

ROCE %

1 Year22.53%
3 Year22.88%
5 Year23.13%

Debt/Equity

0.0018

Price to Cash Flow

17.69

Interest Cover Ratio

84.579

CFO/PAT (5 Yr. Avg.)

0.91741010383651

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2025 49.78 0.00
Dec 2024 49.78 0.00
Sep 2024 49.78 0.00
Jun 2024 49.78 0.00
Mar 2024 49.53 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 0.9304 Cr.
  • Company has been maintaining healthy ROCE of 22.8779063538451% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 84.579.
  • Company’s PEG ratio is 0.485447593561059.
  • The company has an efficient Cash Conversion Cycle of 24.2206 days.
  • Company has a healthy liquidity position with current ratio of 4.0222.

 Limitations

  • The company has shown a poor revenue growth of 11.138324899253% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
Net Sales 142.49 147.28 161.21 146.55 168.18
Total Expenditure 124.11 124.55 132.83 122.89 141.46
Operating Profit 18.38 22.73 28.38 23.66 26.72
Other Income 7.02 10.41 9.98 8.97 -6.88
Interest 0.5 0.44 0.35 0.73 0.37
Depreciation 2.69 3.22 3.22 3.22 3.23
Exceptional Items 0 0 0 0 0
Profit Before Tax 22.22 29.48 34.78 28.68 16.25
Tax 3.62 5.81 8.45 7.91 4.67
Profit After Tax 18.6 23.67 26.33 20.77 11.57
Adjusted EPS (Rs) 9.28 11.82 13.15 10.37 5.78

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 376.09 422.91 472.08 510.31 580.55
Total Expenditure 316.72 335.87 376.61 421.14 480.64
Operating Profit 59.37 87.04 95.47 89.17 99.91
Other Income 12.13 5.74 10 22.48 34.42
Interest 1.98 1.55 1.45 2.03 1.46
Depreciation 5.47 7.56 8.09 9.17 10.62
Exceptional Items 0 0 0 0 0
Profit Before Tax 64.05 83.67 95.93 100.46 122.24
Tax 14.48 21.42 26.57 27.56 28.94
Net Profit 49.56 62.25 69.35 72.9 93.3
Adjusted EPS (Rs.) 24.78 31.08 34.63 36.4 46.58

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 20 20.03 20.03 20.03 20.03
Total Reserves 284.49 346.36 412.85 482.44 572.81
Borrowings 0.52 0.14 0 0 0
Other N/C liabilities 37.47 40.73 41.74 38.02 15.18
Current liabilities 69.44 93.45 110.46 95.85 117.27
Total Liabilities 411.92 500.72 585.08 636.34 725.28
Assets
Net Block 91.03 110.64 131.88 150.53 179.33
Capital WIP 0.04 1.69 16.05 6.71 3.48
Intangible WIP 0 0 0 0 0
Investments 25.79 0.05 0.05 0.05 0.05
Loans & Advances 65.69 61.57 62.57 88.18 70.74
Other N/C Assets 0.03 0.45 1.75 0 0
Current Assets 229.35 326.31 372.78 390.87 471.68
Total Assets 411.92 500.72 585.08 636.34 725.28
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 64.05 83.67 95.93 100.46 122.24
Adjustment 5.38 4.75 1.49 -0.29 -16.76
Changes in Assets & Liabilities 15.27 0.42 2.4 -31.4 -16.12
Tax Paid -13.98 -19.45 -23.64 -29.61 -26.13
Operating Cash Flow 70.71 69.39 76.18 39.16 63.24
Investing Cash Flow -28.99 -64.39 -78.08 -36.64 -57.34
Financing Cash Flow -38.1 -5.74 -2.56 -4.5 -5.18
Net Cash Flow 3.61 -0.74 -4.46 -1.99 0.73

Corporate Actions

Investors Details

PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
promoters 49.53 49.78 49.78 49.78 49.78
aashish rajanibhai patel 10.60 10.60 10.60 10.60 10.60
anand arvinbhai patel 1.66 1.66 1.66 1.66 1.66
arvindbhai gulabdas patel... 0.55 0.55 0.55 0.55 0.55
bhagirathbhai tribhovanda... 0.12 0.12 0.12 0.12 0.12
dharmistaben hasmukhbhai ... 0.32 0.32 0.32 0.32 0.32
dharmisthaben bhagirath p... 0.62 0.62 0.62 0.62 0.62
downtown finance pvt. ltd... 0.53 0.53 0.53 0.53 0.53
downtown travels llp 2.37 2.37 2.37 2.37 2.37
hansaben arvindbhai patel... 0.88 0.88 0.88 0.88 0.88
hashmukhbhai ishwarlal pa... - - - - 1.87
jigar hasmukhbhai patel 0.43 0.43 0.43 0.43 0.43
kailashben mahendrabhai p... 2.40 2.40 2.40 2.40 2.40
mahendrabhai gulabdas pat... 3.37 3.37 3.37 3.37 3.37
mansi munjal patel 1.00 1.00 1.00 1.00 1.00
mihir viththalbhai patel 0.41 0.41 0.41 0.41 0.41
munjal mahendrabhai patel... 13.13 13.37 13.37 13.37 13.37
nidhi mahendrabhai patel 0.27 0.27 0.27 0.27 0.27
patel aniruddh h 0.43 0.43 0.43 0.43 0.43
patel nishitkumar maheshb... 0.77 0.77 0.77 0.77 0.77
rajanikant gulabdas patel... 3.78 3.78 3.78 3.78 3.78
renukaben maheshbhai pate... 0.49 0.49 0.49 0.49 0.49
shivani ashish patel - - 1.03 1.03 1.03
sunmed corporation llp 2.50 2.50 2.50 2.50 2.50
hasmukhbhai ishwarbhai pa... - - - 1.87 -
hashmukhbhai ishwarlal pa... 1.87 1.87 1.87 - -
shivani b. shah 1.03 1.03 - - -
PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
investors 50.47 50.22 50.22 50.22 50.22
dheeraj kumar lohia 1.32 1.32 1.32 1.31 1.30
kishor m. shah 2.39 2.39 2.39 2.39 2.39
llp 0.11 0.16 0.23 0.20 0.22
rimo capital fund lp 1.25 1.25 1.33 1.33 1.33
investor education and pr... 0.26 0.26 - 0.28 -
investor education and pr... - - 0.26 - -
kamlesh jayantilal patel 1.09 1.08 - - -
parikh mitesh jagdishbhai... 1.01 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Lincoln Pharma - Quaterly Results 22 May, 12:36 PM Lincoln Pharma - Quaterly Results 22 May, 12:36 PM Lincoln Pharmaceuticals informs about board meeting 15 May, 2:56 PM Lincoln Pharmaceuticals informs about board meeting 15 May, 12:42 PM Lincoln Pharmaceuticals informs about updates 9 May, 3:18 PM Lincoln Pharmaceuticals informs about confirmation certificate 5 Apr, 2:33 PM Lincoln Pharma - Quaterly Results 13 Feb, 12:21 PM Lincoln Pharma - Quaterly Results 13 Feb, 12:21 PM Lincoln Pharmaceuticals informs about board meeting 5 Feb, 2:54 PM Lincoln Pharmaceuticals informs about clarification 6 Dec, 5:13 PM Lincoln Pharmaceuticals informs about press release 15 Nov, 2:10 PM Lincoln Pharmaceuticals informs about outcome of board meeting 14 Nov, 2:42 PM Lincoln Pharmaceuticals informs about board meeting 5 Nov, 3:11 PM Lincoln Pharmaceuticals informs about compliances-certificate 7 Oct, 4:37 PM Lincoln Pharmaceuticals informs about closure of trading window 23 Sep, 5:19 PM Lincoln Pharma - Quaterly Results 8 Aug, 12:10 PM Lincoln Pharma - Quaterly Results 8 Aug, 12:10 PM Lincoln Pharma - Quaterly Results 8 Aug, 12:10 PM Lincoln Pharmaceuticals informs about disclosure 11 Jun, 11:50 AM Lincoln Pharmaceuticals informs about outcome of board meeting 16 May, 3:13 PM Lincoln Pharma - Quaterly Results 16 May, 12:14 PM Lincoln Pharma - Quaterly Results 16 May, 12:14 PM Lincoln Pharma - Quaterly Results 16 May, 12:14 PM Lincoln Pharmaceuticals informs about newspaper publication 15 May, 5:53 PM Lincoln Pharmaceuticals informs about disclosure 29 Feb, 11:02 AM Lincoln Pharmaceuticals informs about disclosure 29 Feb, 11:01 AM Lincoln Pharmaceuticals informs about disclosure 26 Feb, 2:22 PM Lincoln Pharmaceuticals informs about disclosure 23 Feb, 12:28 PM Lincoln Pharmaceuticals informs about resignation of director 22 Feb, 5:09 PM Lincoln Pharma - Quaterly Results 8 Feb, 12:28 PM Lincoln Pharma - Quaterly Results 8 Feb, 12:28 PM Lincoln Pharma - Quaterly Results 8 Feb, 12:28 PM Lincoln Pharmaceuticals informs about compliances-certificate 8 Jan, 4:34 PM Lincoln Pharmaceuticals informs about newspaper advertisement 3 Nov, 12:53 PM Lincoln Pharmaceuticals informs about outcome of board meeting 2 Nov, 2:47 PM Lincoln Pharmaceuticals informs about outcome of board meeting 2 Nov, 2:34 PM Lincoln Pharma - Quaterly Results 2 Nov, 12:24 PM Lincoln Pharma - Quaterly Results 2 Nov, 12:24 PM Lincoln Pharma - Quaterly Results 2 Nov, 12:24 PM Lincoln Pharmaceuticals informs about newspaper advertisement 26 Aug, 2:59 PM Lincoln Pharmaceuticals informs about press release 11 Aug, 12:18 PM Lincoln Pharma - Quaterly Results 10 Aug, 12:22 PM Lincoln Pharma - Quaterly Results 10 Aug, 12:22 PM Lincoln Pharma - Quaterly Results 10 Aug, 12:22 PM Lincoln Pharmaceuticals informs about press release 26 May, 1:13 PM Lincoln Pharmaceuticals informs about outcome of board meeting 25 May, 3:09 PM Lincoln Pharma - Quaterly Results 25 May, 11:42 AM Lincoln Pharma - Quaterly Results 25 May, 11:42 AM Lincoln Pharma - Quaterly Results 25 May, 11:42 AM Lincoln Pharmaceuticals informs about issuance of duplicate share certificate 12 May, 4:55 PM

Lincoln Pharma Stock Price Analysis and Quick Research Report. Is Lincoln Pharma an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Lincoln Pharma and its performance over the period of time. Lincoln Pharma stock price today is Rs 558.65.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Lincoln Pharma cash from the operating activity was Rs 63.2445 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Lincoln Pharma has a Debt to Equity ratio of 0.0018 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Lincoln Pharma , the EPS growth was 27.9912 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Lincoln Pharma has OPM of 17.2091066809795 % which is a good sign for profitability.
     
  • ROE: Lincoln Pharma have a average ROE of 17.0372 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Lincoln Pharma is Rs 558.65. One can use valuation calculators of ticker to know if Lincoln Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Lincoln Pharma

Lincoln Pharmaceuticals Limited Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Lincoln Pharmaceuticals Limited is a prominent player in the pharmaceutical industry of India. Established in [year], the company has carved a niche for itself by delivering high-quality medicinal products and establishing a strong presence in both domestic and international markets. With a relentless focus on research and development, Lincoln Pharmaceuticals Limited is committed to providing affordable healthcare solutions to its customers.

Lincoln Pharmaceuticals Limited - Share Price

The share price of Lincoln Pharmaceuticals Limited reflects its market valuation and investor sentiment. It is an essential factor to consider for long-term stock investors looking for stock analysis. By analyzing the historical share price movement, investors can gain insights into the performance of the company and make informed investment decisions. Lincoln Pharmaceuticals Limited's share price information can be accessed on our website, along with pre-built screening tools that can assist in understanding the stock dynamics.

Lincoln Pharmaceuticals Limited - Balance Sheet

Analyzing the balance sheet of Lincoln Pharmaceuticals Limited provides a comprehensive understanding of the company's financial health and stability. A strong balance sheet demonstrates the company's ability to meet its short-term and long-term obligations and reflects its overall performance. Our website offers downloadable annual reports where investors can find detailed information about Lincoln Pharmaceuticals Limited's balance sheet. Additionally, our premium features of fair value calculation tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis enable investors to evaluate the inherent value of the stock.

Lincoln Pharmaceuticals Limited - Annual Report

The annual report of Lincoln Pharmaceuticals Limited serves as a valuable source of information for investors. It provides insights into the company's financial performance, business strategies, and future plans. As a long-term stock investor, it is crucial to study the annual report to gain a deeper understanding of the company's operations, competitive position, and growth prospects. At our website, investors can access the downloadable annual reports of Lincoln Pharmaceuticals Limited, facilitating comprehensive stock analysis.

Lincoln Pharmaceuticals Limited - Dividend

Dividends play a significant role in generating income for stock investors. Lincoln Pharmaceuticals Limited has a track record of regularly rewarding its shareholders through dividend payments. Analyzing the dividend history and payout ratio of the company is essential for investors seeking sustainable returns on their investments. Our website offers data on Lincoln Pharmaceuticals Limited's dividend payments, enabling investors to evaluate the stock's income potential.

Lincoln Pharmaceuticals Limited - Quarterly Result

Quarterly results reflect the financial performance of Lincoln Pharmaceuticals Limited for a specific period. As a long-term stock investor, it is crucial to assess the company's quarterly results to gain insights into its revenue growth, profitability, and overall financial stability. Our website provides access to Lincoln Pharmaceuticals Limited's quarterly result data, allowing investors to track the company's progress and make informed investment decisions. Additionally, our fair value calculation tools aid in comprehending the stock's intrinsic value.

Lincoln Pharmaceuticals Limited - Stock Price

The stock price of Lincoln Pharmaceuticals Limited is influenced by various factors such as market trends, company performance, and investor sentiment. Analyzing stock price movements can assist long-term investors in understanding the market's perception of the company's prospects. Our website provides a price chart that displays the historical stock price of Lincoln Pharmaceuticals Limited, helping investors assess the stock's volatility and trends over time.

Lincoln Pharmaceuticals Limited - News

Keeping abreast of the latest news and developments related to Lincoln Pharmaceuticals Limited is crucial for investors. News articles provide insights into the company's operations, new product launches, collaborations, regulatory updates, and other significant events that may impact the stock's performance. Our website offers a comprehensive collection of news articles related to Lincoln Pharmaceuticals Limited, allowing investors to stay informed and make well-informed investment decisions.

Lincoln Pharmaceuticals Limited - Concall Transcripts

Concall transcripts provide a detailed record of the discussions that take place during the company's conference calls with analysts and investors. These transcripts offer valuable insights into the company's management, business strategies, and outlook for the future. Lincoln Pharmaceuticals Limited's concall transcripts are available for download on our website, providing investors with access to essential information for stock analysis and decision-making.

Lincoln Pharmaceuticals Limited - Investor Presentations

Investor presentations serve as a medium for companies to present their strategy and performance to the investment community. Lincoln Pharmaceuticals Limited's investor presentations are a valuable resource for long-term investors seeking detailed information about the company's operations, competitive positioning, growth prospects, and future plans. The downloadable investor presentations available on our website enable investors to gain a comprehensive understanding of Lincoln Pharmaceuticals Limited and make informed investment decisions.

Lincoln Pharmaceuticals Limited - Promoters

Promoters play a crucial role in the success and development of a company. They are responsible for its establishment, growth, and strategic decisions. In the case of Lincoln Pharmaceuticals Limited, the promoters have shown exemplary leadership and have been instrumental in driving the company's growth. Analyzing the background and contributions of the promoters provides valuable insights into the company's stability and long-term prospects.

Lincoln Pharmaceuticals Limited - Shareholders

Lincoln Pharmaceuticals Limited's shareholders form a critical part of the company's ownership structure. A diverse and well-distributed shareholder base indicates a healthy investor interest and confidence in the stock. Understanding the composition of the shareholder base and the involvement of institutional investors provides insights into the market's perception of the stock and its growth potential.

In conclusion, Lincoln Pharmaceuticals Limited offers a comprehensive platform for long-term stock investors seeking detailed stock analysis. Our website provides access to essential information such as company profile, share price, balance sheet, annual reports, dividends, quarterly results, stock price, news, concall transcripts, investor presentations, promoters, and shareholders. With our pre-built screening tools and premium features for fair value calculations, investors can make well-informed decisions and maximize their investment potential. 

Lincoln Pharmaceuticals' Total Reserves Surge

An examination of Lincoln Pharmaceuticals' balance sheet reveals commendable growth in the company's total reserves, climbing from Rs. 284.49 Cr in March 2020 to a robust Rs. 572.81 Cr by March 2024. This indicates a healthy accumulation of retained earnings, which may reflect the company's increasing profitability and solid financial management over the years.

Steady Increase in Lincoln Pharmaceuticals' Assets

Over a span of four years, Lincoln Pharmaceuticals has showcased a steady increase in total assets, from Rs. 411.92 Cr in March 2020 to Rs. 725.28 Cr in March 2024. Notably, the net block and current assets have seen significant upticks, signifying ongoing investments in capital assets and an expansion of operating capacity.

Lincoln Pharmaceuticals Shows Diminishing Debt

One positive highlight from Lincoln Pharmaceuticals' balance sheet is the zero borrowings from March 2022 onwards, indicating the company's successful efforts in deleveraging. This positions Lincoln Pharmaceuticals as a potentially low-risk investment from a debt standpoint.

Lincoln Pharmaceuticals' Equity and Liabilities Pattern

The data further shows a consistent rise in the company's equity from Rs. 20 Cr to Rs. 20.03 Cr, reflecting slight changes in share capital, while total liabilities parallel assets, indicating a balanced growth structure.

Lincoln Pharmaceuticals' Focus on Asset Creation

Capital work-in-progress (WIP) figures peaking at Rs. 16.05 Cr in March 2022 before settling to Rs. 3.48 Cr by March 2024 may signify a strategic shift towards completing ongoing projects and a potential focus on new asset creation or operational efficiency.

This analysis is for the Standalone Balance Sheet of Lincoln Pharmaceuticals, which is crucial information for market participants and constitutes one component among various criteria used in stock screening and evaluation on platforms like NSE and BSE.

Read More
X